If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 38.5(b) - Pfizer Inc.

3 Nov 2015 11:09

RNS Number : 3597E
J.P. Morgan Securities LLC
03 November 2015
Β 

Ap27

Β 

AMENDMENT

FORMΒ 38.5(b)

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 38.5(b)Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DEALINGSΒ BYΒ CONNECTEDΒ EXEMPTΒ PRINCIPALΒ TRADERSΒ WITHOUTΒ RECOGNISEDΒ INTERMEDIARYΒ STATUS,Β ORΒ WITHΒ RECOGNISEDΒ INTERMEDIARYΒ STATUSΒ BUTΒ NOTΒ DEALINGΒ INΒ AΒ CLIENT-SERVINGΒ CAPACITY

Β 

Β 

1. KEYΒ INFORMATION

Β 

Name of exempt principal trader

J.P. Morgan Securities LLC.

Company dealt in

Pfizer Inc

Class of relevant security to which the dealings being disclosed relate (Note 1)

Common Stock

Date of dealing

29 October 2015

Β 

2. INTERESTSΒ ANDΒ SHORTΒ POSITIONS

Β 

(a) InterestsΒ andΒ shortΒ positionsΒ (followingΒ dealing)Β inΒ theΒ classΒ ofΒ relevantΒ securityΒ dealtΒ inΒ (NoteΒ 2)

Β 

Common stock

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

4,887,422 0.08

3,191,054 0.05

(2) Derivatives (other than options)

1,099,067 0.02

2,438,780 0.04

(3) Options and agreements to purchase/sell

3,401,570 0.06

1,883,300 0.03

Total

9,388,059 0.15

7,513,134 0.12

Β 

Β 

Β 

(b) InterestsΒ andΒ shortΒ positionsΒ inΒ relevantΒ securitiesΒ ofΒ theΒ company,Β otherΒ thanΒ theΒ classΒ dealtΒ inΒ (NoteΒ 2)

Β 

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

Β 

Β 

Ap28

Β 

Β 

3. DEALINGSΒ (NoteΒ 3)

Β 

(a) PurchasesΒ andΒ sales

Β 

Purchases/ sales

Β 

Number of relevant securities

Price per unit (USD)

Purchases

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Sales

2,091

42

100,000

15,131

1,513

13,048

600

9,800

3,100

1,972

6,100

6,381

1,200

1,995

2,500

1,200

14,603

800

5,497

47,473

30

293,802

2,220

2,900

5,600

6,000

4,500

7,339

3,300

1,161

5,000

200

2,194

205

10,000

4,400

20,160

15,500

8,641

21,494

5,100

127,806

200

Β 

300

12,700

567

27,700

3,900

3,800

3,000

6,900

300

700

500

100

2,000

300

400

1,694

23,665

8

6,571

6,246

2,520

2,300

100

3,354

9,900

2,050

1,500

100

1,000

1,800

1,200

3,600

28,239

2,058

300

4,400

2,000

200

7,600

1,100

400

3,400

400

400

2,010

2,051

100

100

5,100

800

3,700

100

1,100

6,716

200

81,926

100

4,049

6,550

800

2,208

1,700

200

2,900

1,300

500

100

200

1,500

3,038

5,129

300

4,920

13,780

5,800

7,032

1,700

1,700

900

2,200

600

763

200

14,633

900

1,300

6,365

1,200

3,000

6,520

15,814

300

4,654

900

14,100

800

200

500

800

2,400

700

19

2,500

3,400

1,700

200

2,400

500

3,566

500

100

200

300

2,002

1,401

200

500

2,500

2,500

160,070

5,000

12,500

15,111

150

34.2500

34.4400

34.4800

34.6750

34.6763

34.6800

34.6850

34.6900

34.7050

34.7064

34.7100

34.7124

34.7250

34.7300

34.7400

34.7450

34.7459

34.7500

34.7600

34.7700

34.7900

34.8500

34.8600

35.3000

35.3400

35.7500

35.8167

35.8500

35.8891

35.9500

35.9700

36.0350

36.1000

36.1100

36.1500

36.1600

36.2500

36.2850

36.3000

36.3500

36.3600

36.4000

36.4400

Β 

34.2750

34.2755

34.2800

34.2850

34.2908

34.2955

34.3000

34.3050

34.3100

34.3371

34.3500

34.3600

34.3780

34.3800

34.3900

34.4100

34.4238

34.4300

34.4305

34.4472

34.4505

34.4665

34.4700

34.4709

34.4750

34.4800

34.4813

34.4850

34.4870

34.4875

34.4888

34.4900

34.4906

34.4917

34.4967

34.4991

34.5000

34.5050

34.5100

34.5200

34.5250

34.5253

34.5300

34.5325

34.5350

34.5829

34.6000

34.6200

34.6300

34.6350

34.6500

34.6550

34.6600

34.6690

34.6700

34.6740

34.6800

34.6900

34.7065

34.7075

34.7083

34.7100

34.7150

34.7200

34.7300

34.7400

34.7450

34.7550

34.7600

34.7610

34.7636

34.7650

34.7700

34.7773

34.7800

34.7814

34.7900

34.8068

34.8100

34.8286

34.8317

34.8399

34.8450

34.8453

34.8500

34.8502

34.8513

34.8550

34.8560

34.8600

34.8601

34.8625

34.8627

34.8644

34.8650

34.8700

34.8725

35.3400

35.3450

35.3500

35.4250

35.4400

35.4536

35.4753

35.4756

35.4800

35.4815

35.4900

35.4916

35.4950

35.5000

35.5050

35.5600

35.5719

35.5799

35.6800

36.0400

36.1700

36.2000

36.2112

36.2400

36.2500

36.2825

36.3200

Β 

(b) DerivativesΒ transactionsΒ (otherΒ thanΒ optionsΒ transactions)

Β 

Product name,

e.g. CFD

Nature of transaction

(Note 5)

Number of relevant securities

(Note 6)

Price per unit (USD)

(Note 4)

Β 

(c) OptionsΒ transactionsΒ inΒ respectΒ ofΒ existingΒ relevantΒ securities

Β 

Β 

(i) Writing,Β selling,Β purchasingΒ orΒ varying

Β 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 4)

Β 

Β 

(ii) Exercising

Β 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 4)

+ bought by counterparty at exercise price

Β 

Β 

(d) OtherΒ dealingsΒ (includingΒ transactionsΒ inΒ respectΒ ofΒ newΒ securities)Β (NoteΒ 3)

Β 

Nature of transaction

(Note 7)

Details

Price per unit

(if applicable) (Note 4)

Β 

Ap29

Β 

4. OTHERΒ INFORMATION

Β 

Agreements,Β arrangementsΒ orΒ understandingsΒ relatingΒ toΒ optionsΒ orΒ derivatives

Β 

FullΒ detailsΒ ofΒ anyΒ agreement,Β arrangementΒ orΒ understandingΒ betweenΒ theΒ person disclosingΒ andΒ anyΒ otherΒ personΒ relatingΒ toΒ theΒ votingΒ rightsΒ ofΒ anyΒ relevantΒ securitiesΒ underΒ anyΒ optionΒ referredΒ toΒ onΒ thisΒ formΒ orΒ relatingΒ toΒ theΒ votingΒ rightsΒ orΒ futureΒ acquisitionΒ orΒ disposalΒ ofΒ anyΒ relevantΒ securitiesΒ toΒ whichΒ anyΒ derivative referredΒ toΒ onΒ thisΒ formΒ isΒ referenced.Β IfΒ none,Β thisΒ shouldΒ beΒ stated.

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

IsΒ aΒ SupplementalΒ FormΒ 38.5(b)Β attached?Β (NoteΒ 8) Β YES

Β 

Β 

Date of disclosure

03 November 2015

Contact name

Tung Le

Telephone number

020 7742 7272

Name of offeree/offeror with which connected

Allergan plc

Nature of connection (Note 9)

Adviser to Allergan plc

Β 

Β 

Β 

Β 

SUPPLEMENTALΒ FORMΒ 38.5(b)

Β 

Β 

Β 

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 38.5(b)Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DETAILSΒ OFΒ OPENΒ POSITIONS

Β 

(ThisΒ formΒ shouldΒ beΒ attachedΒ toΒ FormΒ 38.5(b))Β OPENΒ POSITIONSΒ (NoteΒ 1)

Β 

Product name,

e.g. call option

Written or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)(USD)

Type, e.g. American, European etc.

Expiry date

Call option

Purchased

30,000

35.00

American

20/01/17

Call option

Purchased

70,000

37.00

American

20/01/17

Call option

Purchased

108,700

34.91

European

09/11/15

Call option

Purchased

113,900

35.00

American

15/01/16

Call option

Purchased

700

38.00

American

15/01/16

Call option

Purchased

200,000

34.00

American

20/11/15

Call option

Written

Β 

2,500

28.00

American

15/01/16

Call option

Written

14,700

30.00

American

15/01/16

Call option

Written

200

37.00

American

15/01/16

Call option

Written

150,000

37.00

American

15/01/16

Call option

Written

50,000

33.00

American

18/12/15

Call option

Written

47,100

34.00

American

18/12/15

Call option

Written

7,600

32.00

American

15/01/16

Call option

Purchased

383,200

34.71

European

21/05/16

Call option

Purchased

383,200

34.71

European

21/05/16

Call option

Purchased

127,794

35.28

European

03/12/15

Call option

Purchased

120,533

35.66

European

12/01/16

Call option

Purchased

48,943

36.47

European

25/01/16

Call option

Purchased

295,700

36.49

European

05/11/15

Call option

Purchased

295,700

36.49

European

05/11/15

Call option

Purchased

192,000

37.12

European

10/11/15

Call option

Purchased

192,000

37.12

European

10/11/15

Call option

Purchased

200,000

33.00

European

16/12/15

Call option

Written

200,000

33.00

European

16/12/16

Call option

Written

383,200

34.71

European

21/12/15

Call option

Written

295,700

36.49

European

05/11/15

Call option

Written

192,000

37.12

European

10/11/15

Put option

Written

Β 

30,000

35.00

American

20/01/17

Put option

Written

Β 

20,000

35.00

American

20/01/17

Put option

Written

Β 

4,300

30.00

American

15/01/16

Put option

Written

Β 

2,800

28.00

American

15/01/16

Put option

Written

Β 

300

32.00

American

15/01/16

Put option

Written

Β 

150,000

30.00

American

16/09/16

Put option

Written

Β 

100,000

36.00

American

18/03/16

Put option

Written

Β 

32,900

32.00

American

15/01/16

Put option

Purchased

9,200

33.00

American

19/02/16

Put option

Purchased

19,100

31.00

American

19/02/16

Put option

Purchased

5,300

23.00

American

15/01/16

Put option

Purchased

100,000

30.00

American

15/01/16

Put option

Purchased

5,600

25.00

American

15/01/16

Put option

Purchased

250,000

28.00

American

15/01/16

Put option

Written

200,000

33.00

European

16/12/16

Put option

Purchased

450,000

35.00

American

15/01/16

Callable Barrier Reverse Convertible Note

Purchased

183,430

32.71

N/A

21/03/17

Callable Barrier Reverse Convertible Note

Purchased

30,572

32.71

N/A

21/03/17

Auto-callable Barrier Reverse Convertible Note

Purchased

45,984

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Purchased

30,408

34.53

N/A

05/04/16

Equity Linked Note

Purchased

6,740

29.67

N/A

03/02/16

Leveraged Accumulator

Purchased

16,354+

29.12

N/A

12/09/16

Callable Barrier Reverse Convertible Note

Written

183,430

32.71

N/A

21/03/17

Callable Barrier Reverse Convertible Note

Written

30,572

32.71

N/A

21/03/17

Auto-Callable Barrier Reverse Convertible Note

Written

45,984

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Written

30,408

34.53

N/A

05/04/16

Equity Linked Note

Written

6,740

29.67

N/A

03/02/16

Leveraged Accumulator

Written

16,354+

29.12

N/A

12/09/16

Leveraged Accumulator

Written

10,200+

31.70

N/A

04/03/16

Auto-callable Optimization Securities

Written

7,851

27.60

N/A

25/06/20

Equity Linked Note

Written

6,740

29.67

N/A

03/02/16

Callable Barrier Reverse Convertible Note

Written

183,430

32.71

N/A

21/03/17

Callable Barrier Reverse Convertible Note

Written

30,572

32.71

N/A

21/03/17

Auto-Callable Barrier Reverse Convertible Note

Written

45,984

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Written

30,408

34.53

N/A

05/04/16

Leveraged Accumulator

Written

16,354+

29.12

N/A

12/09/16

Put Option

Purchased

457,000

27.50

N/A

11/01/16

Callable Barrier Reverse Convertible

Purchased

22,929

32.71

N/A

21/03/17

Auto-Callable Barrier Reverse Convertible Note

Purchased

7,685

32.53

N/A

15/03/17

Auto-Callable Barrier Reverse Convertible Note

Purchased

11,189

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Purchased

178

2.44

N/A

05/04/2016

+ This instrument is physically settled, and the interest in shares has been calculated as the maximum number of Mylan shares that the counterparty could be obliged to buy at the exercise price

Β 

Notes

Β 

1. WhereΒ thereΒ areΒ openΒ optionΒ positionsΒ orΒ openΒ derivativeΒ positionΒ (exceptΒ forΒ CFDs),Β fullΒ detailsΒ shouldΒ beΒ given.Β FullΒ detailsΒ ofΒ any existingΒ agreementsΒ toΒ purchaseΒ orΒ toΒ sellΒ mustΒ alsoΒ beΒ givenΒ onΒ this form.

Β 

2. ForΒ allΒ pricesΒ andΒ otherΒ monetaryΒ amounts,Β theΒ currencyΒ mustΒ be stated.

Β 

ForΒ fullΒ detailsΒ ofΒ disclosureΒ requirements,Β seeΒ RulesΒ 8Β and

38.5Β ofΒ theΒ Rules.Β IfΒ inΒ doubt,Β consultΒ theΒ Panel.

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ISEFSUFFDFISESF
Date   Source Headline
7th May 201411:20 amBUSForm 8.3 - Pfizer Inc
7th May 201410:40 amRNSForm 8.5 (EPT/RI) astrazeneca PLC
7th May 201410:38 amRNSForm 8.5 (EPT/RI) Astrazeneca PLC
7th May 201410:36 amRNSForm 8.5 (EPT/RI) Pfizer INC
7th May 201410:31 amRNSRule 2.10 Announcement
7th May 201410:30 amRNSForm 8.5 (EPT/RI) Astrazeneca PLC
7th May 201410:29 amRNSForm 8.5 (EPT/RI) Pfizer Inc
7th May 20147:00 amRNSBENEFITS OF A COMBINATION WITH ASTRAZENECA
7th May 20147:00 amRNSForm 8.5 (EPT/NON-RI)
6th May 20146:16 pmRNSForm 8 (DD) - [Pfizer Inc] - Amendment
6th May 20146:08 pmRNSForm 8.5 (EPT/NON-RI)(OPD)
6th May 20145:15 pmRNSForm 8 (DD) - Pfizer Inc.
6th May 20144:46 pmRNSForm 8.3 - Pfizer Inc
6th May 20144:42 pmRNSForm 8.3 - Pfizer Inc
6th May 20144:16 pmRNSForm 8.5 (EPT/RI)replacement - Pfizer Inc
6th May 20144:14 pmRNSForm 8.5 (EPT/RI) Replacement - Pfizer Inc
6th May 20144:11 pmRNSForm 8.5 (EPT/RI)Replacement - Pfizer Inc
6th May 20144:07 pmRNSForm 8.5 (EPT/RI)Replacement - Pfizer Inc
6th May 20144:05 pmRNSForm 8.5 (EPT/RI) Replacement - Pfizer Inc
6th May 20144:04 pmRNSForm 8.5 (EPT/RI)replacement - Pfizer Inc
6th May 20144:02 pmBUSForm 8.3 - PFIZER INC
6th May 20143:56 pmRNSForm 8.5 (EPT/RI)Replacement - Astrazeneca PLC
6th May 20143:53 pmRNSForm 8.5 (EPT/RI) Replacement - Astrazeneca PLC
6th May 20143:51 pmRNSForm 8.5 (EPT/RI)Replacement - Astrazeneca PLC
6th May 20143:51 pmRNSForm 8.5 (EPT/RI)Replacement - Astrazeneca PLC
6th May 20143:49 pmRNSForm 8.5 (EPT/RI) Replacement - Astrazeneca PLC
6th May 20143:46 pmRNSForm 8.5 (EPT/RI)replacement - Astrazeneca PLC
6th May 20143:34 pmRNSForm 8.3 - Pfizer Inc
6th May 20143:23 pmRNSForm 8.3 - Pfizer Inc
6th May 20143:19 pmRNSForm 8.3 - Pfizer Inc
6th May 20143:19 pmRNSForm 8.3 - Pfizer Inc
6th May 20143:18 pmRNSForm 8.3 - astrazeneca plc
6th May 20143:16 pmRNSForm 8.3 - PFIZER INC
6th May 20143:15 pmRNSForm 8.3 - AstraZeneca Plc
6th May 20143:14 pmBUSForm 8.3 - Pfizer Inc.
6th May 20143:00 pmRNSForm 8.3 - Pfizer Inc.
6th May 20142:51 pmRNSForm 8.3 - [PFIZER INC]
6th May 20142:48 pmBUSForm 8.3 - Pfizer Inc
6th May 20142:31 pmRNSForm 8.3 - [Pfizer/Astrazeneca]
6th May 20141:54 pmRNSForm 8.3 - Pfizer Inc
6th May 20141:48 pmRNSForm 8.3 - AstraZeneca Plc
6th May 20141:28 pmRNSForm 8.3 - Pfizer Inc
6th May 20141:25 pmRNSForm 8.3 - AstraZeneca Plc
6th May 20141:20 pmRNSForm 8.3 - [AstraZeneca Plc]
6th May 20141:14 pmBUSForm 8.3 - Pfizer Inc.
6th May 20141:13 pmRNSForm 8.5 (EPT/RI)
6th May 20141:09 pmRNSForm 8.5 (EPT/NON-RI)
6th May 20141:07 pmBUSForm 8.3 - Pfizer Inc.
6th May 20141:06 pmRNSForm 8.5 (EPT/RI)
6th May 201412:35 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.